Luis Kress

Luis Kress

Auto-generated profile, based on publicly available information

Luis Kress

TRON Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2026 in BioHackrXiv
Verified
Preprint
Open access
MAManar Abdalazem
Manar Abdalazem
FBFelix Bartusch
Felix Bartusch
EBEd Bennett
Ed Bennett
OBOliver But
Oliver But
BCBen Carillo
Ben Carillo
WWWytamma Wirth
Wytamma Wirth
Reproducible, scalable, and portable data-analysis pipelines are now a fundamental prerequisite for modern data analysis research across all research domains. Snakemake has emerged as one of the most widely adopted systems for declarative pipeline orchestration, combining a concise Python-based DSL with native support for containers, cloud back-ends, and fine-grained provenance tracking, and it underpins thousands of published studies. Nonetheless, the platform’s continued evolution faces several open challenges: improving core performance on heterogeneous high-performance-computing (HPC) resources, extending the plugin architecture for domain-specific extensions, and lowering the entry barrier for novice users while preserving full reproducibility.Here we report on the Snakemake Hackathon 2026, convened in Munich, Germany (9–13 March 2026) with more than 40 participants representing academia, industry, and national-level research infrastructure.

3 July 2026 in bioRxiv
Verified
Preprint
Open access
JHJohannes Hausmann
Johannes Hausmann
FLFranziska Lang
Franziska Lang
ÖMÖzlem Muslu
Özlem Muslu
LKLuis Kress
Luis Kress
JLJonathan J M Landry
Jonathan J M Landry
JIJonas Ibn-Salem
Jonas Ibn-Salem
Individualized cancer immunotherapies rely on tumor-specific T-cell antigens, often predicted from somatic mutations as neoantigens. For tumors with low mutational burden, mRNA transcript variants, including gene fusions and novel splice junctions, can serve as important alternative targets. A main challenge in their identification from tumor RNA-seq is to confirm that their expression is tumor-restricted. Although large public collections of healthy-tissue RNA-seq exist, verifying tumor-specific expression requires computationally expensive re-analysis of these data for every novel candi-date. To address this, we benchmarked nine k-mer indexing algorithms and devel-oped k4neo, which leverages k-mer indexing of raw RNA-seq reads to compute the tumor specificity of any transcript variant. This mapping-free and transcript-class ag-nostic approach screens any candidate sequence against 18,960 samples across 51 healthy tissue types. We confirmed k4neo's detection accuracy with qRT-PCR and showed that k4neo accurately classifies somatic and germline variants, gene fusions, and isoforms by tumor specificity. Applied to nine tumor cohorts, it nominated a medi-an of 4-80 tumor-specific splice junctions per patient, including recurrent, long-read-validated novel antigen candidates. Together, k4neo enables efficient access to large-scale sequencing cohorts and accurately computes tumor specificity for any in-put transcript sequence, thereby expanding the repertoire of individual and shared cancer antigen targets.